ChenGuang Biotech Group Co., Ltd. (SHE:300138)
China flag China · Delayed Price · Currency is CNY
11.36
-0.05 (-0.44%)
Sep 14, 2026, 3:04 PM CST

ChenGuang Biotech Group Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
5,8296,0495,8035,6715,0743,950
Other Revenue
231.63509.61,1911,2001,222923.77
6,0616,5596,9946,8726,2964,874
Revenue Growth
-15.36%-6.22%1.79%9.14%29.18%24.55%
Cost of Revenue
5,3115,7356,5356,0725,4524,175
Gross Profit
749.66824.38459.36799.37843.87698.53
Selling, General & Admin
212.73228.04208.33213.08249.21210.35
Research & Development
123.3166.24128.697.4129.0394.79
Other Operating Expenses
24.5112.91-1.787.0916.8213.66
Operating Expenses
368.15412.09335.27318.45395.16319.48
Operating Income
381.51412.29124.1480.92448.71379.05
Interest Expense
-92.23-90.83-114.42-83.51-67.21-53.15
Interest & Investment Income
62.5584.8158.36104.2863.2739.58
Currency Exchange Gain (Loss)
-11.4-0.665.542.4121.37-5.63
Other Non Operating Income (Expenses)
-0.94-3.41-34.033.31-2.367.61
EBT Excluding Unusual Items
339.49402.239.55507.43463.78367.46
Gain (Loss) on Sale of Investments
3.029.27-5.115.36-5.020.56
Gain (Loss) on Sale of Assets
-2.51.464.89-0.631.080.1
Asset Writedown
-8.28-6.94-0.46-1.1-1.32-10.91
Other Unusual Items
53.4731.8868.0844.7643.2440.85
Pretax Income
385.21437.87106.95555.82501.76398.07
Income Tax Expense
47.362.9928.9961.6565.6747.47
Earnings From Continuing Operations
337.91374.8877.96494.17436.09350.6
Minority Interest in Earnings
-5.48-616.09-14.45-2.050.92
Net Income
332.43368.8794.05479.72434.03351.51
Net Income to Common
332.43368.8794.05479.72434.03351.51
Net Income Growth
58.92%292.21%-80.40%10.53%23.47%31.29%
Shares Outstanding (Basic)
480483517532533529
Shares Outstanding (Diluted)
480483517532533529
Shares Change
-3.78%-6.62%-2.76%-0.14%0.80%4.13%
EPS (Basic)
0.690.760.180.900.810.67
EPS (Diluted)
0.690.760.180.900.810.67
EPS Growth
65.16%320.02%-79.84%10.68%22.49%26.09%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-538.5177.65-372.35-777.67558.78-216.92
Free Cash Flow Per Share
-1.120.16-0.72-1.461.05-0.41
Dividend Per Share
0.3000.3000.1300.1300.1600.130
Dividend Growth
130.77%130.77%0%-18.75%23.08%30.00%
Gross Margin
12.37%12.57%6.57%11.63%13.40%14.33%
Operating Margin
6.30%6.29%1.77%7.00%7.13%7.78%
Profit Margin
5.49%5.62%1.34%6.98%6.89%7.21%
Free Cash Flow Margin
-8.88%1.18%-5.32%-11.32%8.88%-4.45%
EBITDA
561.66594.82290.76633.47593.27509.67
EBITDA Margin
9.27%9.07%4.16%9.22%9.42%10.46%
D&A For EBITDA
180.14182.53166.67152.54144.56130.62
EBIT
381.51412.29124.1480.92448.71379.05
EBIT Margin
6.30%6.29%1.77%7.00%7.13%7.78%
Effective Tax Rate
12.28%14.39%27.11%11.09%13.09%11.92%
Revenue as Reported
6,0616,5596,9946,8726,2964,874